Challenges in diagnosis and treatment of sporadic inclusion-body myositis

被引:0
|
作者
Sebastian, Agata [1 ]
Misterska-Skora, Maria [1 ]
Sebastian, Maciej [2 ]
Krecichwost, Roksana [3 ]
Haczkiewicz, Katarzyna [4 ]
机构
[1] Wroclaw Med Univ, Fac Med, Dept Rheumatol & Internal Med, Wroclaw, Poland
[2] Wroclaw Med Univ, Fac Med, Dept Minimally Invas Surg & Proctol, Wroclaw, Poland
[3] Wroclaw Med Univ, Fac Med, Dept Ophthalmol, Wroclaw, Poland
[4] Wroclaw Med Univ, Fac Med, Dept Histol & Embryol, Wroclaw, Poland
来源
基金
英国医学研究理事会;
关键词
biomarker; early diagnosis; sporadic inclusion body myositis; IDIOPATHIC INFLAMMATORY MYOPATHIES; SKELETAL-MUSCLES; RIMMED VACUOLES; EXPRESSION; AUTOANTIBODIES; ALEMTUZUMAB; PROTEINS; UPDATE; PHASE; CELLS;
D O I
10.17219/acem/69855
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Sporadic inclusion body myositis (sIBM) is a rare yet increasingly prevalent disease and the most common cause of inflammatory myopathy in people over the age of 50. The exact cause of the disorder is unknown. In sIBM 2 processes, first autoimmune and the other degenerative, parallelly occur in the muscle cells. The inflammation aspect is characterized by the cloning of T cells that appear to be driven by specific antigens to invade muscle fibers. The degeneration aspect is characterized by the appearance of holes in the muscle cell vacuoles, deposits of abnormal proteins within the cells and in filamentous inclusions. The disease has a major impact on patients' motor functionality and their quality of life. The treatment of sIBM still remains a major challenge. Early diagnosis of sIBM (already at the histopathology stage), when one still cannot observe fully developed clinical symptoms, may stop help to the progression of the disease.
引用
收藏
页码:1453 / 1457
页数:5
相关论文
共 50 条
  • [21] A perspective on sporadic inclusion-body myositis - The role of aging and inflammatory processes
    Finch, CE
    NEUROLOGY, 2006, 66 : S1 - S6
  • [22] Neurodegeneration-associated proteins and inflammation in sporadic inclusion-body myositis
    Lampe, JB
    Walter, MC
    Reichmann, H
    NEUROPATHOLOGY AND GENETICS OF DEMENTIA, 2001, 487 : 219 - 228
  • [23] Upregulation of antioxidative enzyme peroxiredoxin 5 in sporadic inclusion-body myositis
    Yang, F
    Wang, M
    Wei, A
    Knoops, B
    Ouvrier, R
    Pollard, J
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2002, 199 : S51 - S51
  • [24] MAGNETIC RESONANCE IMAGING PATTERN RECOGNITION IN SPORADIC INCLUSION-BODY MYOSITIS
    Tasca, Giorgio
    Monforte, Mauro
    De Fino, Chiara
    Kley, Rudolf A.
    Ricci, Enzo
    Mirabella, Massimiliano
    MUSCLE & NERVE, 2015, 52 (06) : 956 - 962
  • [25] Increased aging in primary muscle cultures of sporadic inclusion-body myositis
    Morosetti, Roberta
    Broccolini, Aldobrando
    Sancricca, Cristina
    Gliubizzi, Carla
    Gidaro, Teresa
    Tonali, Pietro A.
    Ricci, Enzo
    Mirabella, Massimiliano
    NEUROBIOLOGY OF AGING, 2010, 31 (07) : 1205 - 1214
  • [26] Sporadic inclusion-body myositis: Recent advances and the state of the art in 2016
    Gallay, L.
    Petiot, P.
    REVUE NEUROLOGIQUE, 2016, 172 (10) : 581 - 586
  • [27] INCLUSION-BODY MYOSITIS AND MYOPATHIES
    GRIGGS, RC
    ASKANAS, V
    DIMAURO, S
    ENGEL, A
    KARPATI, G
    MENDELL, JR
    ROWLAND, LP
    ANNALS OF NEUROLOGY, 1995, 38 (05) : 705 - 713
  • [28] Genetics of inclusion-body myositis
    Needham, M.
    Mastaglia, F. L.
    Garlepp, M. J.
    MUSCLE & NERVE, 2007, 35 (05) : 549 - 561
  • [29] Pilot trial of etanercept in the treatment of inclusion-body myositis
    Barohn, RJ
    Herbelin, L
    Kissel, JT
    King, W
    McVey, AL
    Saperstein, DS
    Mendell, JR
    NEUROLOGY, 2006, 66 : S123 - S124